Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
61.49
-1.76 (-2.78%)
Aug 14, 2025, 11:54 AM - Market open
Cidara Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 510.58 | 189.83 | 35.78 | 32.73 | 59.68 | 35.91 | Upgrade
|
| Cash & Short-Term Investments | 510.58 | 189.83 | 35.78 | 32.73 | 59.68 | 35.91 | Upgrade
|
| Cash Growth | 210.63% | 430.56% | 9.31% | -45.16% | 66.18% | -28.56% | Upgrade
|
| Accounts Receivable | 1.86 | 1.69 | 14.08 | 5.72 | 5.36 | 11.18 | Upgrade
|
| Receivables | 1.86 | 1.69 | 14.08 | 5.72 | 5.36 | 11.18 | Upgrade
|
| Prepaid Expenses | 13.02 | 12.87 | 1.71 | 5.58 | 4.07 | 3.07 | Upgrade
|
| Restricted Cash | 6.34 | 6.35 | - | - | 2.59 | 7.04 | Upgrade
|
| Other Current Assets | - | - | 9.29 | 1.07 | - | - | Upgrade
|
| Total Current Assets | 531.79 | 210.74 | 60.86 | 45.09 | 71.7 | 57.19 | Upgrade
|
| Property, Plant & Equipment | 2.44 | 3.96 | 5.13 | 1.32 | 2.54 | 1.21 | Upgrade
|
| Other Long-Term Assets | 0.1 | 0.1 | 1.05 | 1.07 | 1.08 | 2.02 | Upgrade
|
| Total Assets | 534.33 | 214.8 | 67.03 | 47.49 | 75.33 | 60.42 | Upgrade
|
| Accounts Payable | 2.21 | 3.61 | 3.77 | 1.45 | 1.3 | 4.57 | Upgrade
|
| Accrued Expenses | 28.62 | 44.3 | 37.25 | 24.13 | 15.06 | 12.17 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 2.59 | 7.02 | Upgrade
|
| Current Portion of Leases | 1.5 | 1.64 | 1.3 | 1.21 | 1.15 | 0.94 | Upgrade
|
| Current Unearned Revenue | - | - | 0.43 | 1 | 13.92 | 13.87 | Upgrade
|
| Other Current Liabilities | - | - | 24.67 | 13.61 | - | - | Upgrade
|
| Total Current Liabilities | 32.32 | 49.55 | 67.42 | 41.4 | 34.02 | 38.56 | Upgrade
|
| Long-Term Leases | 0.84 | 1.93 | 3.58 | - | 1.32 | - | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | - | 18.41 | 11.15 | Upgrade
|
| Other Long-Term Liabilities | - | - | 4.25 | 20.53 | - | - | Upgrade
|
| Total Liabilities | 33.15 | 51.49 | 75.24 | 61.93 | 53.75 | 49.71 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0.01 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,162 | 774.57 | 433.22 | 404.06 | 398.73 | 345.41 | Upgrade
|
| Retained Earnings | -660.46 | -611.26 | -441.43 | -418.5 | -377.17 | -334.7 | Upgrade
|
| Total Common Equity | 501.17 | 163.31 | -8.21 | -14.44 | 21.57 | 10.72 | Upgrade
|
| Shareholders' Equity | 501.17 | 163.31 | -8.21 | -14.44 | 21.57 | 10.72 | Upgrade
|
| Total Liabilities & Equity | 534.33 | 214.8 | 67.03 | 47.49 | 75.33 | 60.42 | Upgrade
|
| Total Debt | 2.33 | 3.58 | 4.88 | 1.21 | 5.06 | 7.96 | Upgrade
|
| Net Cash (Debt) | 508.24 | 186.25 | 30.9 | 31.52 | 54.62 | 27.95 | Upgrade
|
| Net Cash Growth | 217.51% | 502.73% | -1.96% | -42.29% | 95.42% | -27.48% | Upgrade
|
| Net Cash Per Share | 44.17 | 29.33 | 7.07 | 9.02 | 20.83 | 13.45 | Upgrade
|
| Filing Date Shares Outstanding | 25.36 | 10.95 | 10.95 | 4.45 | 3.41 | 2.4 | Upgrade
|
| Total Common Shares Outstanding | 23.23 | 10.95 | 4.53 | 3.62 | 3.39 | 2.24 | Upgrade
|
| Working Capital | 499.47 | 161.18 | -6.56 | 3.69 | 37.68 | 18.63 | Upgrade
|
| Book Value Per Share | 21.57 | 14.92 | -1.81 | -3.98 | 6.36 | 4.78 | Upgrade
|
| Tangible Book Value | 501.17 | 163.31 | -8.21 | -14.44 | 21.57 | 10.72 | Upgrade
|
| Tangible Book Value Per Share | 21.57 | 14.92 | -1.81 | -3.98 | 6.36 | 4.78 | Upgrade
|
| Machinery | - | 3.44 | 3.32 | 2.96 | 3.06 | 2.97 | Upgrade
|
| Leasehold Improvements | - | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | Upgrade
|
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.